Skip to content

An Individual's Lived Experiences of Taking Cannabis-Based Medicinal Products (CBMPs) to Treat Anxiety.

Samantha Hurn

International Journal of Environmental Research and Public Health September 18, 2023 DOI: 10.3390/ijerph20186776 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Autoethnography (n-of-1 case report within a clinical trial) Peer reviewed
Sample size 1
Population The author, a patient with chronic treatment-refractive anxiety and other mental health conditions linked to childhood abuse
Interventions Cannabis-based medicinal products (CBMPs) medical cannabis (Cannabis sativa L.)
Duration First four months of the trial
Topics Anxiety Cannabis
Keywords Humans Female Medical marijuana Medical anthropology Lived experience Autoethnography Cbmps
Key findings The author reports that cannabis-based medicinal products had a positive impact on her chronic anxiety, which had previously been refractory to conventional and alternative treatments, within the first four months of the Sapphire Access Scheme trial. She presents this as a preliminary autoethnographic account of her lived experience.

Abstract

This report documents the case of a patient (the author) participating in a clinical trial of medical cannabis (Cannabis sativa L.)-the Sapphire Access Scheme, run by the Sapphire Medical Clinic as part of the UK Medical Cannabis Registry-to explore the impacts of cannabis-based medicinal products (CBMPs) on anxiety. For most of my life, I have experienced often very serious bouts of poor mental health arising, in part, from childhood abuse, and have been diagnosed with several mental health conditions which constitute disabilities. I have received various conventional treatments and multiple alternative therapies. However, none of these have enabled me to consistently manage my conditions long-term, and I often suffer relapses. As part of the Sapphire Access Scheme, I complete regular quantitative questionnaires regarding the impacts of the CBMPs on my anxiety and have also obtained the clinic's permission to qualitatively document and write up the impacts of CBMPs on my mental health. Here, I present a preliminary autoethnographic exploration of my lived experiences of CBMP use over the first four months of the trial, which show that even within such a short space of time, CBMPs have had a positive impact on treating what had previously been treatment-refractive chronic anxiety.

Comparable studies

Other non-randomized and open-label trials on cannabis, most cited first.

Study Year Design Participants
Feasibility of a cannabidiol-dominant cannabis-based medicinal product for the treatment of long COVID symptoms: A single-arm open-label feasibility trial. Individuals diagnosed with long COVID 2024 Single-arm open-label feasibility trial n = 12
A proposal to evaluate mechanistic efficacy of hallucinogens in addiction treatment Prescription opioid abusers 2013 Proposed clinical trial
Does acute stress induced via cold water immersion increase blood THC concentrations in regular cannabis users? Regular cannabis users (more than 3 days per week; 9 female, average use 5.0 ± 1.5 days... 2025 Single-arm pre-/post-intervention trial n = 15
Understanding marijuana's effects on functional connectivity of the default mode network in patients with schizophrenia and co-occurring cannabis use disorder: A pilot investigation. Patients with schizophrenia and cannabis use disorder (n=12) and healthy controls (n=12) 2018 Pilot study n = 24
An Ethno‐Methodological Approach to Cannabis and Music Perception, with EEG Brain Mapping in a Naturalistic Setting Habituated cannabis consumers in a naturalistic setting 2006 Ethnographic pre/post study with single case studies n = 4

Explore topics

By condition and practice